Our Company has access to an impressive pipeline of technology opportunities originating from the Partners HealthCare research network as well as from a large number of Russian research institutions. To date Boston BioCom has initiated development of two specific programs.

Laser Immunomodulation Program: Applies novel insights on modification of the skin's immune system by non-destructive laser energy to create applications in vaccine adjuvants as well as direct immunotherapy. Read more..

New-Generation Antibody Program: Comprises several novel classes of monoclonal antibodies invented at the Massachusetts General Hospital and facilitated by a Russian technology platform. These antibodies are being developed mainly for oncology and infectious diseases. Read more..

In addition, the Company is actively evaluating two new technology platform opportunities:

Boston BioCom is progressing on the early development of a new technology plat-form to address the huge unmet market need in the treatment of shock caused by traumatic injury. Based on research both in Russia and at Harvard, the Company is exploring the necessary collaborations and partnerships to advance this therapeutic approach.

Traumatic Shock: Boston BioCom is progressing on the early development of a new technology platform that could move quickly to address a huge market. Read more..

A program to develop new laser treatments for neurodegenerative eye disease. Insights from the laser immunomodulation program are being applied to ophthalmology in order to evaluate the potential for non-destructive laser treatment of the retina to prevent the loss of vision in a number of eye diseases.

These programs represent revolutionary, transformational approaches to the treatment of the diseases that they address. The figure below shows the prioritized technology programs by technology type and therapeutic focus.